Abstract:Background: Most people are infected with COVID-19 during pandemics at the end of 2022. Older patients were more vulnerable. However, the incidence of secondary bacterial, fungal or viral pulmonary infection and co-infection is not well described in elderly hospitalized COVID-19 patients. Methods: We retrospectively reviewed the medical records of all elderly (≥65 years) hospitalized patients with laboratory-confirmed COVID-19 from December 1, 2022 to January 31, 2023. Demographics, underlying diseases, treatments, and laboratory data were collected. Univariate and multivariate logistic regression models were used to explore the risk factors associated with secondary bacterial, fungal or viral pulmonary infection and co-infection. Results: A total of 322 older patients with COVID-19 were enrolled. The incidence of secondary bacterial, fungal or viral pulmonary infection and co-infection was 27.3% (88/322) and 7.5% (24/322), respectively. The overall in-hospital mortality of all patients was 32.9% (106/322), and the in-hospital mortality among patients who acquired with secondary pulmonary infection and co-infection was 57.0% (57/100). A total of 23.9% (77/322) of patients were admitted to ICU within 48 h of hospitalization. The incidence of secondary pulmonary infection and co-infection among patients admitted to the ICU was 50.6% (39/77) and 13.0% (10/77), respectively. The overall in-hospital mortality of ICU patients was 48.1% (37/77), and the in-hospital mortality of ICU patients acquired with secondary pulmonary infection and co-infection was 61.4% (27/44). A total of 83.5% (269/322) of the included patients received empirical antibiotic therapy before positive Clinical Microbiology results. Influenza A virus (the vast majority were the H3N2 subtype) was the most common community acquired pathogen for co-infection. While A. baumannii, K. pneumoniae, and P. aeruginosa were the common hospital acquired pathogens for co-infection and secondary pulmonary infection. The incidence of Carbapenem-resistant Gram-negative bacilli (CR-GNB) infections was high, and the mortality reached 76.9%. Predictors of secondary pulmonary infection and co-infection were ICU admission within 48 h of hospitalization, cerebrovascular diseases, critical COVID-19, and PCT > 0.5 ng/mL. Conclusion: The prognosis for elderly hospitalized COVID-19 patients with secondary pulmonary infection or co-infection is poor. The inflammatory biomarker PCT > 0.5 ng/mL played an important role in the early prediction of secondary pulmonary infection and co-infection in COVID-19 patients.

COVID-19 related secondary bacterial pneumonia ~Comparisons with influenza～

Development of secondary bacterial pneumonia in adults presenting with influenza versus noninfluenza viral respiratory infection

A case report demonstrating the utility of next generation sequencing in analyzing serial samples from the lung following an infection with influenza A (H7N9) virus.

Bacterial microbiota in upper respiratory tract of COVID-19 and influenza patients

SHP2 Deficiency Promotes Staphylococcus Aureus Pneumonia Following Influenza Infection

Secondary Bacterial Infections in Patients With Viral Pneumonia

A comparison of demographic, epidemiological and clinical characteristics of hospital influenza-related viral pneumonia patients

Secondary infections in critically ill patients with viral pneumonia due to COVID-19 and influenza: a historical cohort study

Pathogen analysis of bacterial pneumonia secondary to influenza

Impact of Coinfection with SARS-CoV-2 and Influenza on Disease Severity: A Systematic Review and Meta-Analysis

Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients

Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19

Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09

Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: An observational study

Secondary infection with Streptococcus pneumoniae decreases influenza virus replication and is linked to severe disease

The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza

Determinants of poor clinical outcome in patients with influenza pneumonia: A systematic review and meta-analysis

Risk factors for in-hospital mortality and secondary bacterial pneumonia among hospitalized adult patients with community-acquired influenza: a large retrospective cohort study

Bacterial co-infections in community-acquired pneumonia caused by SARS-CoV-2, influenza virus and respiratory syncytial virus

Diagnostic significance of secondary bacteremia in patients with COVID-19